Major Developments in Health Sector: Weight-Loss Breakthroughs and Policy Shifts

A roundup of recent health news highlights policy changes affecting FDA language use, drug industry meetings with President Trump, advances in weight-loss drugs preserving muscle mass, AstraZeneca's strategic acquisition in China, and Canada's bird flu vaccine purchase. Other briefs cover changes in US health definitions and Pope Francis's health condition.

Federal policy shifts have raised eyebrows as FDA staffers reportedly received guidance to exclude terms like 'woman' and 'disabled' in official communications. A White House official deems these actions a misinterpretation of President Trump's executive orders.

The competitive race for weight-loss treatments continues as pharmaceutical companies shift focus towards drugs that preserve muscle mass while aiding in fat reduction. Leaders in the industry, including Novo Nordisk and Eli Lilly, have developed medications that, despite effectiveness in weight reduction, also cause muscle loss, posing potential health risks.

Meanwhile, AstraZeneca’s $160 million acquisition of FibroGen's China unit highlights strategic expansion amidst US-China trade tensions. Concurrently, the Canadian government strengthens preparedness against avian flu by purchasing half a million doses of GSK’s vaccine.